Sirolimus
Classic Familial Adenomatous Polyposis
Explore 11 assets in Classic Familial Adenomatous Polyposis →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University Hospital, Toulouse
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06308445CT.gov Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis | — | Not Yet Recruiting | — | — | — |
NCT06950385CT.gov Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | — | Recruiting | — | — | — |
NCT04230499CT.gov Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance | — | Active Not Recruiting | — | — | — |
NCT03095703CT.gov Sirolimus and Familial Adenomatous Polyposis (FAP) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Familial Adenomatous Polyposis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirolimus (this asset) | University Hospital, Toulouse | P3 | B · 62 |
| Eflornithine | Cancer Prevention Pharmaceuticals, Inc. | P3 | BB |
| EPA | S.L.A. Pharma AG | P3 | BB |
| Azithromycin | Tel-Aviv Sourasky Medical Center | P4 | BB |
| Celecoxib | Yonsei University | P3 | BB |
| Sulindac | Cancer Prevention Pharmaceuticals, Inc. | P3 | BB |
| Erythromycin | michal roll | P4 | BB |
| Metformin | Yonsei University | P3 | BB |
| Rofecoxib | Merck Sharp & Dohme LLC | P4 | B |
+17 more in the Classic Familial Adenomatous Polyposis cohort
Other indications for Sirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 73 |
| Disease Related To Transplantation | — | P4 | BBB · 72 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sirolimus in Classic Familial Adenomatous Polyposis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sirolimus-classic-familial-adenomatous-polyposis-118985
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →